Last update May 1, 2016

Hydroxycarbamide

Low Risk

Moderately safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Used for the treatment of myeloproliferative disorders (polycythemia vera, essential thrombocythemia, myeloid leukemia, myeloid splenomegaly), certain cancers and prevention of recurrent painful occlusive crisis in sickle cell anemia from older than 2 years old .

It is excreted in breast milk in small amounts, below 10% of relative adult dose or theoretical dose in pediatric patients, so it is not expected the occurrence of side effects on the breastfed infant whose mother is receiving this treatment.

Risk may be lowered, especially in infants younger than 3 months, by delaying breastfeeding from 12 to 24 hours after dose.
Whenever a long-term treatment is desired monitoring of blood count in the infant should be considered.

Alternatives

We do not have alternatives for Hydroxycarbamide.

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Hydroxycarbamide is also known as


Hydroxycarbamide in other languages or writings:

Group

Hydroxycarbamide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Hydroxycarbamide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 100 %
Molecular weight 76 daltons
VD 1.3 l/Kg
Tmax 1 - 2 hours
3 - 4 hours
Theoretical Dose 0.6 - 1.3 mg/Kg/d
Relative Dose 2.3 - 4.9 %
Ped.Relat.Dose 2 - 8.7 %

References

  1. EMA. Hydroxyurea. Drug Summary. 2014 Full text (in our servers)
  2. EMA. Hidroxicarbamida. Ficha técnica. 2014 Full text (in our servers)
  3. Rodriguez GI, Kuhn JG, Weiss GR, Hilsenbeck SG, Eckardt JR, Thurman A, Rinaldi DA, Hodges S, Von Hoff DD, Rowinsky EK. A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood. 1998 Abstract Full text (link to original source) Full text (in our servers)
  4. Thornley S, Manoharan A. Successful treatment of essential thrombocythemia with alpha interferon during pregnancy. Eur J Haematol. 1994 Jan;52(1):63-4. No abstract available. Abstract
  5. Sylvester RK, Lobell M, Teresi ME, Brundage D, Dubowy R. Excretion of hydroxyurea into milk. Cancer. 1987 Abstract Full text (in our servers)

Total visits

5,663

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by IHAN of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM